Study of genes associated with aberrant methylation regulation in high-grade meningiomas

doi:10.3969/j.issn.1006-7795.2023.05.007

Journal of Capital Medical University ›› 2023, Vol. 44 ›› Issue (5): 747-752.doi: 10.3969/j.issn.1006-7795.2023.05.007

Previous Articles Next Articles

Study of genes associated with aberrant methylation regulation in high-grade meningiomas

Peng Yichen, Zheng Yi, Li Shenglan, Yu Jianyu, Lan Yanjie, Liu Xinrui, Chen Feng, Li Wenbin^*

Department of Neuro-oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China

Received:2023-07-18 Online:2023-10-20 Published:2023-10-25
Supported by:
This study was supported by Clinical Major Specialty Project of Beijing.

Abstract

Abstract: Objective To explore potential therapeutic targets with bioinformatics for the treatment of meningiomas, the most common primary central nervous system tumors. Methods A preliminary understanding of the genomic characteristics of high-grade meningiomas was obtained through analysis of public databases to assess the genes associated with aberrant methylation regulation. Results A total of 3 006 genes whose expression was regulated by aberrant methylation were identified, including 210 genes with high mutation frequency, and pathways associated with malignant tumor development and migration were mined. Conclusions Genes and related pathways potentially regulated by aberrant methylation in high-grade meningioma provides bio-markers and potential therapeutic targets for high-grade meningioma.

Key words: high-grade meningioma, aberrant methylation, signaling pathway

CLC Number:

R739.45

Peng Yichen, Zheng Yi, Li Shenglan, Yu Jianyu, Lan Yanjie, Liu Xinrui, Chen Feng, Li Wenbin. Study of genes associated with aberrant methylation regulation in high-grade meningiomas[J]. Journal of Capital Medical University, 2023, 44(5): 747-752.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2023.05.007

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2023/V44/I5/747

References

［1］Louis D N, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary［J］. Neuro Oncol, 2021, 23(8): 1231-1251.
［2］Ostrom Q T, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012［J］. Neuro Oncol, 2015, 17(Suppl 4): ⅳ1-ⅳ62.
［3］Ostrom Q T, Gittleman H, Xu J, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013［J］. Neuro Oncol, 2016, 18(suppl_5): v1-v75.
［4］Maggio I, Franceschi E, Tosoni A, et al. Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas［J］. CNS Oncol, 2021, 10(2): CNS72.
［5］Simpson D. The recurrence of intracranial meningiomas after surgical treatment［J］. J Neurol Neurosurg Psychiatry, 1957, 20(1): 22-39.
［6］Goldbrunner R, Stavrinou P, Jenkinson M D, et al. EANO guideline on the diagnosis and management of meningiomas［J］. Neuro Oncol, 2021, 23(11): 1821-1834.
［7］Kim L. A narrative review of targeted therapies in meningioma［J］. Chin Clin Oncol, 2020, 9(6): 76.
［8］Xu X M, Peng Q, Jiang X J, et al. Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential［J］. Exp Mol Med, 2023, 55(7): 1357-1370.
［9］Zimmerman S M,Lin P N,Souroullas G P. Non-canonical functions of EZH2 in cancer［J］.Front Oncol, 2023, 13: 1233953.
［10］Manna S, Mishra J, Baral T, et al. Epigenetic signaling and crosstalk in regulation of gene expression and disease progression［J］.Epigenomics, 2023, 15(14): 723-740.
［11］Cerami E, Gao A A, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data［J］. Cancer Discov, 2012, 2(5): 401-404.
［12］Higgins D, Shah A H, Komotar R J, et al. Management of atypical and anaplastic meningiomas［J］. Neurosurg Clin N Am, 2023, 34(3): 437-446.
［13］Bi W L, Greenwald N F, Abedalthagafi M, et al. Genomic landscape of high-grade meningiomas［J］. NPJ Genom Med, 2017, 2: 15.
［14］Graillon T, Sanson M, Campello C, et al. Everolimus and octreotide for patients with recurrent meningioma: results from the phase Ⅱ CEVOREM trial［J］. Clin Cancer Res, 2020, 26(3): 552-557.
［15］Marastoni E, Barresi V. Meningioma grading beyond histopathology: relevance of epigenetic and genetic features to predict clinical outcome［J］. Cancers (Basel), 2023, 15(11): 2945.
［16］ Greenberg M V C, Bourchis D. The diverse roles of DNA methylation in mammalian development and disease［J］. Nat Rev Mol Cell Biol, 2019, 20(10): 590-607.
［17］Zhang F F, Zhang X, Zhang H K, et al. Pan-precancer and cancer DNA methylation profiles revealed significant tissue specificity of interrupted biological processes in tumorigenesis［J］. Epigenetics, 2023, 18(1): 2231222.
［18］Bird A, Taggart M, Frommer M, et al. A fraction of the mouse genome that is derived from islands of nonmethylated, CpG-rich DNA［J］. Cell, 1985, 40(1): 91-99.
［19］Jeltsch A, Gowher H. Editorial-role of DNA methyltransferases in the epigenome［J］. Genes (Basel), 2019, 10(8): 574.

[1]	Liu Fengjun;Fang Min;Jin Chonghua;Jiang Zhongli. Ophthalmological Findings and Prognosis in Patients with Sphenoid Ridge Meningioma [J]. Journal of Capital Medical University, 2004, 25(4): 531-533.
[2]	Yang Jun;Sun Yilin;Wang Guihuai;Zhang Maozhi. A Study on Ultrastructure and Clinic Management of Recurrent Meningiomas [J]. Journal of Capital Medical University, 2000, 21(2): 149-151.

Study of genes associated with aberrant methylation regulation in high-grade meningiomas

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 2

Recommended Articles

Metrics

Comments